Pal Rashmi Saxena, Wahlang Jenny, Pal Yogendra, Chaitanya Mvnl, Saxena Sumedha
Lovely Professional University, Phagwara, India.
CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar, Punjab, India.
Med Oncol. 2025 Jun 9;42(7):246. doi: 10.1007/s12032-025-02817-y.
Precision medicine has revolutionized cancer treatment by enabling highly personalized therapeutic strategies based on an individual's genetic, molecular, and environmental characteristics. Advances in next-generation sequencing (NGS), molecular profiling, and biomarker-driven approaches have enhanced diagnostic accuracy and optimized treatment selection. Targeted therapies, immunotherapy, and liquid biopsy techniques have significantly improved patient outcomes while minimizing adverse effects compared to conventional treatments. Despite these advancements, challenges such as tumor heterogeneity, treatment resistance, high costs, and limited accessibility continue to hinder widespread clinical adoption. While tumour heterogeneity presents a major obstacle in cancer treatment, the challenge is further compounded by the complexity of the tumour microenvironment, where dynamic interactions between cancer cells and surrounding stromal components drive disease progression. Additionally, ethical concerns regarding genetic data privacy and disparities in access to precision oncology require further attention. This review highlights the transformative impact of precision medicine in oncology, emphasizing its benefits, limitations, and the need for continued research. Future advancements in artificial intelligence, multi-omics integration, and adaptive clinical trial designs will be critical in overcoming current challenges and expanding precision medicine's applicability across diverse cancer types. With ongoing innovations, precision oncology has the potential to redefine cancer care, making tailored treatments more accessible, effective, and widely implementable.
精准医学通过基于个体的基因、分子和环境特征制定高度个性化的治疗策略,彻底改变了癌症治疗方式。下一代测序(NGS)、分子图谱分析和生物标志物驱动方法的进展提高了诊断准确性并优化了治疗选择。与传统治疗相比,靶向治疗、免疫治疗和液体活检技术显著改善了患者预后,同时将不良反应降至最低。尽管取得了这些进展,但肿瘤异质性、治疗耐药性、高成本和可及性有限等挑战仍继续阻碍其在临床上的广泛应用。虽然肿瘤异质性是癌症治疗中的一个主要障碍,但肿瘤微环境的复杂性使这一挑战更加复杂,癌细胞与周围基质成分之间的动态相互作用推动了疾病进展。此外,关于遗传数据隐私的伦理问题以及精准肿瘤学可及性方面的差异也需要进一步关注。本综述强调了精准医学在肿瘤学中的变革性影响,强调了其益处、局限性以及持续研究的必要性。人工智能、多组学整合和适应性临床试验设计方面的未来进展对于克服当前挑战以及扩大精准医学在各种癌症类型中的适用性至关重要。随着不断创新,精准肿瘤学有可能重新定义癌症治疗,使定制化治疗更容易获得、更有效且更广泛地得以实施。